Indications
Coughs associated with viral upper respiratory tract infections.
Action
Reduces viscosity of tenacious secretions by increasing
respiratory tract fluid. Therapeutic Effects: Mobilization
and subsequent expectoration of mucus.
Pharmacokinetics
Absorption: Well absorbed after oral administration.
Distribution: Unknown.
Metabolism and Excretion: Renally excreted as
metabolites.
Half-life: Unknown.
TIME/ACTION PROFILE (expectorant action)
ROUTE ONSET PEAK DURATION
PO 30 min unknown 4–6 hr
PO-ER unknown unknown 12 hr
Contraindications/Precautions
Contraindicated in: Hypersensitivity; Some products
contain alcohol; Avoid in patients with known intolerance;
Some products contain aspartame and
should be avoided in patients with phenylketonuria.
Use Cautiously in: Cough lasting 1 wk or accompanied
by fever, rash, or headache; Patients receiving
disulfiram (liquid products may contain alcohol); Diabetic
patients (some products may contain sugar); OB:
Although safety has not been established, guaifenesin
has been used without adverse effects; Pedi: OTC cough
and cold products containing this medication should be
avoided in children 4 yr. Adverse Reactions/Side Effects
CNS: dizziness, headache. GI: nausea, diarrhea, stomach
pain, vomiting. Derm: rash, urticaria.
Interactions
Drug-Drug: None significant.
Route/Dosage
PO (Adults): 200–400 mg q 4 hr or 600–1200 mg q
12 hr as extended-release product (not to exceed 2400
mg/day).
PO (Children 6–12 yr): 100–200 mg q 4 hr or 600
mg q 12 hr as extended-release product (not to exceed
1200 mg/day).
PO (Children 4–6 yr): 50–100 mg q 4 hr (not to
exceed 600 mg/day).
Availability (generic available)
Syrup: 100 mg/5 mLOTC. Oral solution: 100 mg/5
mLRx, OTC, 200 mg/5 mLOTC. Capsules: 200 mgOTC. Tablets:
100 mgOTC, 200 mgRx, OTC, 1200 mg. Extendedrelease
tablets (Mucinex): 600 mg, 1200 mg. In
combination with: hydrocodone (Flowtuss, Obredon);
hydrocodone and pseudoephedrine (Hycofenix);
analgesics/antipyretics, antihistamines, decongestants,
and cough suppressants. See Appendix B.
No comments:
Post a Comment